Search clinical trials for: melanoma vaccine

Total 13279 results

Ludwig Institute for Cancer Research
Bristol-Myers Squibb

Terminated

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Metastatic Melanoma

Australia
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA

Terminated

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

United States, Australia
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
Nina Bhardwaj
Memorial Sloan Kettering Cancer Center; NYU Langone Health; Ludwig Institute... and other collaborators

Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Melanoma

United States
Morphogenesis, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Completed

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV

United States
Roswell Park Cancer Institute

Terminated

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
Genocea Biosciences, Inc.

Completed

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Renal Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Urothelial Carcinoma | Cutaneous Melanoma

United States
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Hasumi International Research Foundation

Active, not recruiting

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

Melanoma, Uveal Metastatic

Germany
Gary Doolittle

Completed

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma (MARVSmALo)

Melanoma

United States
National Cancer Institute (NCI)

Terminated

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Melanoma | Sarcoma | Thoracic Sarcomas | Thorasic Cancers | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

United States
Herlev Hospital

Active, not recruiting

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac)

Non Small Cell Lung Cancer Metastatic | Malignant Melanoma, Metastatic | Bladder Urothelial Carcinoma, Metastatic

Denmark
Polynoma LLC

Terminated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

Melanoma

United States, Canada
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of Southern California; University... and other collaborators

Completed

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage... and other conditions

United States
M.D. Anderson Cancer Center

Completed

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Melanoma

United States
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Malignant Melanoma

Norway
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Vaccinex Inc.

Terminated

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Bart Neyns
Vrije Universiteit Brussel

Completed

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
Dana-Farber Cancer Institute
Boston Children's Hospital

Completed

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

Melanoma | Renal Cell Carcinoma | Sarcoma, Clear Cell | Sarcoma, Alveolar Soft Part

United States
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study (ABSIDE)

Malignant Melanoma of Skin Stage III | Malignant Melanoma of Skin Stage IV

Italy
Steinar Aamdal

Terminated

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

Norway
BioNTech US Inc.
Bristol-Myers Squibb

Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Melanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder Tumors

United States
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States
Patrick Ott, MD

Completed

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Melanoma

United States
GlaxoSmithKline

Completed

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Melanoma

Germany, Czechia, France, Italy, Russian Federation, Poland
BioNTech US Inc.
Apexigen, Inc.

Terminated

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Metastatic Melanoma

United States
Jonsson Comprehensive Cancer Center
Pfizer

Completed

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
National Cancer Institute (NCI)

Terminated

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Melanoma | Colon Cancer | Gastrointestinal Cancer | Hepatocellular Cancer | Genitourinary Cancer

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Advanced Malignant Melanoma

Malignant Melanoma

United States
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Xiangya Hospital of Central South University

Unknown

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin)

China
Massachusetts General Hospital

Completed

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Melanoma | Glioblastoma | Intracranial Tumors

United States
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients. (ACDC)

Malignant Melanoma | Adjuvant Drug Therapy | Vaccin Therapy

Italy
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Melanoma | Sarcoma | Epithelial Malignancies | Pleural Malignancies

United States
Craig L Slingluff, Jr

Completed

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (MEL37)

Melanoma

United States
Hospital Italiano de Buenos Aires
University of Buenos Aires; National Council of Scientific and Technical Research... and other collaborators

Terminated

Suicide Plus Immune Gene Therapy for Advanced Melanoma (IGTM-101)

Melanoma

Argentina
Michael Har-Noy
Hadassah Medical Organization

Completed

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Melanoma | Sarcoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Cancer | Solid Tumors Stage II, Stage III and Stage IV

Israel
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
BioNTech RNA Pharmaceuticals GmbH

Completed

IVAC MUTANOME Phase I Clinical Trial

Melanoma

Austria, Germany

Search clinical trials for: melanoma vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations